June 1, 2003European Journal of Heart Failure
Update of Clinical Trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-Wave Alternans
Key result
A review of clinical trials from the ACC 2003 highlights new roles for aldosterone antagonists in heart failure, potential warfarin substitutes, and the need for targeted statin therapy.
Population
Patients with heart failure and other cardiovascular conditions discussed in the ACC 2003 trials.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Provides 2003 trial context without altering practice; leaves open modern applicability of those findings.
Structured PICO
P
Population
Patients with heart failure and other cardiovascular conditions discussed in the ACC 2003 trials.
I
Intervention
Various interventions including aldosterone antagonists, warfarin substitutes, statins, cardiac resynchronisation devices, implantable defibrillators, dual chamber pacing, and T-wave alternans.
This review summarizes key clinical trials presented at ACC 2003, highlighting significant updates in heart failure management, anticoagulation, and device therapy.
Limitations
- COMPANION study results were inconclusive and/or hard to interpret
- T-wave alternans technology needs testing in an appropriate patient population
Cite This Study
Cleland et al. (2003) conducted a review in Heart failure and cardiovascular disease. Various cardiovascular therapies was evaluated. A review of clinical trials from the ACC 2003 highlights new roles for aldosterone antagonists in heart failure, potential warfarin substitutes, and the need for targeted statin therapy.